BC Innovations | Nov 15, 2019
Product Development

Minerva on the verge in neuropsychiatry with two compounds close to verdict

Minerva Neurosciences is on the precipice of two clinical readouts that could determine whether its founding bet on a pair of neuropsychiatry compounds from Mitsubishi Tanabe has panned out. Neither molecule represents a shift from...
BC Innovations | Sep 26, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Pseudomonas Cell culture studies suggest inhibition of P. aeruginosa sodB or combined inhibition of P. aeruginosa relA and spoT could help treat chronic infections by the bacteria and prevent drug resistance. In stationary-phase P....
BC Innovations | Jul 20, 2017
Product R&D

Eureka moment for TCR mimics

In the race to access the wealth of intracellular molecular targets once considered undruggable, Eureka Therapeutics Inc. is pioneering TCR -like antibodies that capitalize on the ability of TCRs to recognize tumor antigens. But the...
BC Week In Review | Nov 11, 2016
Clinical News

Bremelanotide: Ph III data

Top-line data from a total of 1,202 premenopausal women with HSDD in the modified intent-to-treat (mITT) populations of the identical, 24-week, double-blind, U.S. and Canadian Phase III Reconnect Studies 301 and 302 showed that 1.75...
BioCentury | May 30, 2016
Strategy

Taking Takeda global

Two years after joining Takeda Pharmaceutical Co. Ltd. , Christophe Weber has narrowed the company's therapeutic focus, expanded the executive team and reorganized its approach to market with the aim of transforming the company into a...
BC Innovations | Oct 22, 2015
Distillery Therapeutics

Therapeutics: Wilms tumor 1 (WT1); CD3e molecule epsilon (CD3-TCR complex)(CD3ε; CD3E)

Cancer INDICATION: Cancer; leukemia Cell culture and mouse studies suggest a bispecific T cell engager (BiTE) antibody targeting WT1 and CD3ε could help treat cancer and leukemia. The BiTE consisted of ESK1 - which is a...
BC Week In Review | Jan 19, 2015
Clinical News

Bremelanotide: Phase III started

Palatin began the 32-week, double-blind, placebo-controlled, North American Phase III reconnect study to evaluate subcutaneous bremelanotide self-administered as needed in about 550 premenopausal women with hypoactive sexual desire disorder (HSDD) -- a subtype of FSD....
BC Week In Review | Aug 4, 2014
Clinical News

Tefina: Phase II data

The double-blind, international Phase II AMB-2012-01 trial in 253 pre- and post-menopausal women experiencing acquired female orgasmic disorder showed that 0.6 mg Tefina as needed for 84 days met the primary endpoint of improving the...
BC Innovations | Feb 20, 2014
Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Mucopolysaccharidosis a-l-iduronidase (IDUA) In vitro and mouse studies suggest megakaryocyte-targeted gene therapy could help treat mucopolysaccharidosis I (MPS I; Hurler syndrome). In a human...
BC Week In Review | Oct 21, 2013
Company News

Genetic Alliance other news

Genetic Alliance issued a request for proposals to offer its crowd-sourced Platform for Engaging Everyone Responsibly (PEER). Genetic Alliance will offer a customized, organization-branded installation of PEER to up to nine disease and/or condition advocacy...
Items per page:
1 - 10 of 17